These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25217402)

  • 1. Omalizumab: a review of its use in patients with chronic spontaneous urticaria.
    McCormack PL
    Drugs; 2014 Sep; 74(14):1693-9. PubMed ID: 25217402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic autoimmune urticaria with omalizumab.
    Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
    Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
    J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
    Lang DM
    Drugs Today (Barc); 2015 Jun; 51(6):367-74. PubMed ID: 26261850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of omalizumab in the treatment of chronic urticaria.
    Stitt JM; Dreskin SC
    Immunotherapy; 2014; 6(6):691-7. PubMed ID: 25186602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab for the treatment of chronic urticaria.
    Zuberbier T; Maurer M
    Expert Rev Clin Immunol; 2015 Feb; 11(2):171-80. PubMed ID: 25566680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
    Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
    Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
    Wieder S; Maurer M; Lebwohl M
    Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.
    Macglashan DW; Saini SS
    J Allergy Clin Immunol; 2013 Oct; 132(4):906-11.e1-4. PubMed ID: 23791510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
    Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
    Wu KCP; Jabbar-Lopez ZK
    J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic idiopathic urticaria: treatment with omalizumab.
    Naaman S; Sussman G
    Skin Therapy Lett; 2014; 19(6):1-4. PubMed ID: 25807072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.